Drugs / LZM009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03286296 | Aug 2017 → Mar 2019 | cancer | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-16 | Bright Peak Therapeutics Inc | Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines brightpeaktx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LZM009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03286296 ↗ |
| Action | Inhibit | “anti-PD-1 monoclonal antibody” NCT03286296 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-PD-1 monoclonal antibody” NCT03286296 ↗ |
| Route | Intravenous | “administrated intravenously” NCT03286296 ↗ |